Sanofi has completed the $3.2 billion acquisition of US biotech Translate Bio after the tender offer for all shares expired as scheduled at midnight US Eastern Daylight Time on Sept. 4. The minimum tender condition and all of the other conditions to the offer were satisfied, the French drugmaker said.
French drugmaker Sanofi may reconsider plans to acquire Translate Bio at the conditions recently announced, the US biotech said in a filing with the US Securities and Exchange Commission (SEC). Translate said Sanofi withdrew and refiled the proposed buyout information recently provided to allow the FTC more time to study it.
French drugmaker Sanofi has signed a definitive agreement to acquire Translate Bio, the clinical-stage mRNA therapeutics company with which it is currently cooperating on a Covid-19 vaccine. Both boards have unanimously approved the proposed all-cash transaction.
Sanofi Pasteur, the vaccines global business unit of French drugmaker Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are formally expanding their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases.
